Last reviewed · How we verify

ChiRhoStim

ChiRhoClin, Inc. · FDA-approved active Small molecule

ChiRhoStim is a secretin receptor agonist that stimulates pancreatic secretion and gastrointestinal motility.

ChiRhoStim is a secretin receptor agonist that stimulates pancreatic secretion and gastrointestinal motility. Used for Pancreatic exocrine insufficiency.

At a glance

Generic nameChiRhoStim
SponsorChiRhoClin, Inc.
Drug classSecretin receptor agonist
TargetSecretin receptor
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

The drug activates secretin receptors on pancreatic acinar cells and gastrointestinal smooth muscle, enhancing pancreatic enzyme and bicarbonate secretion while improving gastric and intestinal motility. This mechanism supports digestive function and may improve nutrient absorption in patients with pancreatic insufficiency or motility disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: